Three key details:
1. The drug, selonsertib, failed to improve NASH symptoms in the study, which took place two months after a previous study during which the drug failed. NASH is a nonalcoholic fatty liver disease that can cause fatigue, nausea and weight loss.
2. The trial involved patients with compensated cirrhosis, an advanced form of NASH.
3. In a statement, John McHutchison, chief scientific officer and head of research and development for Gilead Sciences, said: “We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways involved in the pathogenesis of this disease.”
More articles on gastroenterology:
4 statistics on GI workload
5 must-read articles for GI leaders
CRH posts $29M in revenue for Q1 2019 — 6 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
